The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track program after agency scientists flagged safety and efficacy concerns, ...

Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive ...

A new obesity drug that Eli Lilly is researching but hasn't approved is turning up online, even though it's not supposed to be available.

Patients also have to deal with changes to their health insurance at the start of a new year, and more employers have ...

Compounding pharmacy sues Eli Lilly and Novo Nordisk alleging antitrust violations to restrict compounded GLP-1 medication access and limit competition.

In a separate development, Eli Lilly and Company (NYSE:LLY) announced on January 7 that it entered into a definitive ...

Disc Medicine (IRON) stock and Sanofi (SNY) stock are in focus as the FDA delays reviews of their drugs selected for National Priority Review vouchers. Read more here.

The rising popularity of weight loss drugs is a key reason healthcare company Eli Lilly (NYSE: LLY) has been soaring in value ...

According to firm-reported figures, Morgan & Morgan had 295 cases go to trial which ultimately resolved favorably for the plaintiff. The firm secured $1,098,230,342 in jury verdicts for its clients, ...

The new drugs could become the way forward for medicated weight loss as clinical trials reveal optimistic results ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

CRISPR Therapeutics analysis: long-term upside despite volatility. Track Casgevy ramp, pipeline milestones & cash runway.